In an international clinical trial published in The Lancet Diabetes & Endocrinology, Jing Luo, MD, MPH, and colleagues found that long-acting insulin glargine reduced dangerous hypoglycemia over time among children and young adults in Bangladesh and Tanzania.
Jing Luo and Colleagues Study Newer Insulin for Type 1 Diabetes in Low-Resource Settings
